Safety and Efficacy Study of Adalimumab in the Treatment of Plaque Psoriasis

Inclusion Criteria

• •Clinical diagnosis of psoriasis for at least 6 months.
• •Must have stable plaque psoriasis for at least 2 months before screening and baseline visits.
• •Participant must have a Psoriasis Area Severity Index score greater than or equal to 10 at the baseline visit.
• •Participant must have moderate to severe plaque Psoriasis, defined by Body Surface Area involvement greater than or equal to 10% at the baseline visit.
• •Participant must have a Physicians Global Assessment of at least moderate disease at baseline visit.